2009
Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis
Qamar AA, Grace ND, Groszmann RJ, Garcia–Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia–Pagan J, Patch D, Matloff DS, Makuch R, Rendon G, Group P. Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis. Clinical Gastroenterology And Hepatology 2009, 7: 689-695. PMID: 19281860, PMCID: PMC4545534, DOI: 10.1016/j.cgh.2009.02.021.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientHematologic indicesCompensated cirrhosisBaseline hepatic venous pressure gradientWhite blood cell countChild-Pugh scorePredictors of deathPrimary end pointVenous pressure gradientDevelopment of varicesKaplan-Meier analysisBlood cell countCombination of leukopeniaBaseline thrombocytopeniaVariceal bleedingClinical decompensationEsophageal varicesPrognostic significanceTransplant surgeryClinical significanceLeukopeniaThrombocytopeniaCirrhosisCell countVarices
2000
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Silverstein F, Faich G, Goldstein J, Simon L, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal N, Stenson W, Burr A, Zhao W, Kent J, Lefkowith J, Verburg K, Geis G. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial. JAMA 2000, 284: 1247-1255. PMID: 10979111, DOI: 10.1001/jama.284.10.1247.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidAspirinCelecoxibCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDiclofenacDouble-Blind MethodFemaleGastrointestinal DiseasesHumansIbuprofenIsoenzymesMaleMembrane ProteinsMiddle AgedOsteoarthritisPeptic UlcerProportional Hazards ModelsProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesSulfonamidesConceptsNonsteroidal anti-inflammatory drugsConventional nonsteroidal anti-inflammatory drugsCelecoxib Long-term Arthritis Safety StudyCOX-2-specific inhibitorsUlcer complicationsSymptomatic ulcersAnti-inflammatory drugsRheumatoid arthritisIncidence rateAspirin useLower incidenceChronic GI blood lossToxic effectsAdverse effectsCelecoxib-treated patientsUpper GI toxicityUpper GI ulcersGI blood lossInhibition of cyclooxygenaseGI intoleranceCardiovascular eventsGastrointestinal toxicityGI toxicityImportant toxic effectsStudy drugThe Stroke Prognosis Instrument II (SPI-II)
Kernan W, Viscoli C, Brass L, Makuch R, Sarrel P, Roberts R, Gent M, Rothwell P, Sacco R, Liu R, Boden-Albala B, Horwitz R. The Stroke Prognosis Instrument II (SPI-II). Stroke 2000, 31: 456-462. PMID: 10657422, DOI: 10.1161/01.str.31.2.456.Peer-Reviewed Original ResearchConceptsRisk groups ICongestive heart failurePooled rateRisk groupsGroup IPrior strokeSPI-IIHeart failureOutcome ratesTest cohortPooled outcome ratesTransient ischemic attackCoronary artery diseasePatient risk groupsStroke Prognosis Instrument IIReceiver operator characteristic analysisOperator characteristic analysisIschemic attackIschemic strokeArtery diseaseIndex eventPatient counselingNew predictive variablesStrokeTotal scoreBlood Pressure Exceeding National Guidelines Among Women After Stroke
Kernan W, Viscoli C, Brass L, Makuch R, Sarrel P, Horwitz R. Blood Pressure Exceeding National Guidelines Among Women After Stroke. Stroke 2000, 31: 415-419. PMID: 10657415, DOI: 10.1161/01.str.31.2.415.Peer-Reviewed Original ResearchConceptsHistory of hypertensionBlood pressure valuesNational guidelinesBlood pressureFirst examinationTrial of estrogenSecondary stroke preventionTransient ischemic attackBlood pressure controlTreatment of hypertensionProportion of womenIschemic attackSevere hypertensionStroke preventionSecondary preventionDiabetic patientsMean ageHypertensionPatientsPressure valuesPersonal physicianPressure controlSeparate guidelinesStrokeWomen
1996
Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation
Horwitz R, Singer B, Makuch R, Viscoli C. Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. Journal Of Clinical Epidemiology 1996, 49: 395-400. PMID: 8621989, DOI: 10.1016/0895-4356(95)00058-5.Peer-Reviewed Original ResearchConceptsClinical inquiryBeta-Blocker Heart Attack TrialCoronary artery surgeryHeart Attack TrialSubgroup of patientsArtery surgeryAspirin useCoronary surgeryMulticenter RCTClinical featuresAttack TrialClinical centersClinical conditionsTreatment groupsPatientsBenefit of propranololClinical decisionTrial resultsHeterogeneous groupPropranololRCTsSurgeryTreatmentTrialsOverall benefit
1995
Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease
Price L, Spencer D, Marek K, Robbins R, Leranth C, Farhi A, Naftolin F, Roth R, Bunney B, Hoffer P, Makuch R, Redmond D. Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. Biological Psychiatry 1995, 38: 498-505. PMID: 8562661, DOI: 10.1016/0006-3223(95)00129-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBrain Tissue TransplantationCaudate NucleusDepressive DisorderDopamineFemaleFetal Tissue TransplantationFollow-Up StudiesHumansMaleMesencephalonMiddle AgedNeurocognitive DisordersNeuropsychological TestsPanic DisorderParkinson DiseasePostoperative ComplicationsProspective StudiesConceptsParkinson's diseasePsychiatric statusHuman fetal mesencephalic tissueAdrenal medullary graftsAdrenal medullary transplantationFetal mesencephalic tissueSystematic psychiatric assessmentPerioperative sequelaeMesencephalic tissuePsychiatric sequelaeCaudate nucleusPsychiatric assessmentNeurobiological effectsBehavioral symptomsTissue transplantationDiseasePatientsTransplantationSequelaeSuch episodesEpisodesGroup effectsStatusDeliriumDiscrete episodes
1993
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.
Murren J, Ganpule S, Papac R, Son Y, Peschel R, Durivage H, Buzaid A, Lamb L, Makuch R, Hait W. A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 1993, 5: 53-7. PMID: 8395915.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerMedian survival timeMitomycin CComplete respondersLung cancerSurvival timeUnresectable stage III non-small cell lung cancerStage III non-small cell lung cancerUnresectable non-small cell lung cancerDay 1Concurrent mitomycin CPhase II trialOverall response rateX-irradiationModerate stomatitisSustained remissionII trialSplit courseWeek restMedian durationContinuous infusionSimultaneous administrationRadiation therapyResponse rate
1991
High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma
Murren J, Derosa W, Durivage H, Davis C, Makuch R, Portlock C. High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 1991, 67: 1514-1517. PMID: 2001539, DOI: 10.1002/1097-0142(19910315)67:6<1514::aid-cncr2820670609>3.0.co;2-q.Peer-Reviewed Original Research
1990
Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation.
Johnson B, Grayson J, Makuch R, Linnoila R, Anderson M, Cohen M, Glatstein E, Minna J, Ihde D. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Journal Of Clinical Oncology 1990, 8: 396-401. PMID: 2155310, DOI: 10.1200/jco.1990.8.3.396.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerLung cancerLung cancer 2Initiation of chemotherapyTen-year survivalCell lung cancerTherapeutic clinical trialsCranial irradiationCombination chemotherapyOriginal malignancySecond cancersClinical trialsHigh riskPatientsCancer 2CancerChemotherapyMalignancyMore yearsCauseYearsChestDiagnosisTrials
1986
Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
Ihde D, Deisseroth A, Lichter A, Bunn P, Carney D, Cohen M, Veach S, Makuch R, Johnston-Early A, Abrams R. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 1443-54. PMID: 3020181, DOI: 10.1200/jco.1986.4.10.1443.Peer-Reviewed Original ResearchConceptsExtensive-stage SCLC patientsProphylactic cranial irradiationComplete responseAutologous bone marrowPartial responseSCLC patientsModality therapyTumor regressionMedical conditionsExtensive-stage small-cell lung cancer patientsExtensive-stage small-cell lung cancerSmall cell lung cancer patientsAutologous bone marrow infusionMajor non-hematologic toxicitySmall cell lung cancerExtensive-stage patientsNon-hematologic toxicitiesWeeks of cyclophosphamideWeeks of vincristineBone marrow infusionGood medical conditionPoor medical conditionLung cancer patientsBetter tumor regressionCranial irradiationA trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.
Seifter E, Bunn P, Cohen M, Makuch R, Dunnick N, Javadpour N, Bensimon H, Eddy J, Minna J, Ihde D. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. Journal Of Clinical Oncology 1986, 4: 1365-73. PMID: 2943877, DOI: 10.1200/jco.1986.4.9.1365.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinClinical Trials as TopicCyclophosphamideDiethylstilbestrolDoxorubicinDrug Therapy, CombinationHumansMaleMedroxyprogesteroneMedroxyprogesterone AcetateMiddle AgedNeoplasm MetastasisOrchiectomyPilot ProjectsProstatic NeoplasmsConceptsHormonal therapyCombination chemotherapyStable diseasePartial responseHormonal manipulationResponse rateInitial hormonal therapySubsequent hormonal manipulationUntreated metastatic carcinomaObjective response rateIntensive combination chemotherapyNormal testosterone levelsMetastatic prostate cancerEfficacy of chemotherapyProgression of diseaseTime of deathSimilar chemotherapyEndocrine treatmentUntreated patientsObjective responseOverall survivalMetastatic carcinomaModest efficacySerum testosteroneProstate cancerCombined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Winkler C, Sausville E, Ihde D, Fischmann A, Schechter G, Kumar P, Nibhanupdi J, Minna J, Makuch R, Eddy J. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. Journal Of Clinical Oncology 1986, 4: 1094-100. PMID: 3088220, DOI: 10.1200/jco.1986.4.7.1094.Peer-Reviewed Original ResearchConceptsTotal skin electron beam irradiationStage I patientsCutaneous T-cell lymphomaDisease-free survivalT-cell lymphomaI patientsStage IIComplete responseModality treatmentCell lymphomaStage IMedian disease-free survivalDisease-free survivorsThree-drug regimensCombined modality treatmentAdvanced-stage patientsOverall response rateOral corticosteroidsAdvanced diseaseSystemic chemotherapyProtocol treatmentTopical therapyStage patientsCR rateSimultaneous chemotherapyPulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
Brooks B, Seifter E, Walsh T, Lichter A, Bunn P, Zabell A, Johnston-Early A, Edison M, Makuch R, Cohen M. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 200-9. PMID: 3003259, DOI: 10.1200/jco.1986.4.2.200.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHumansLomustineLung NeoplasmsMaleMethotrexateMiddle AgedProcarbazinePrognosisProspective StudiesPulmonary FibrosisRadiographyRandom AllocationRespiratory Function TestsVincristineConceptsPulmonary function testsLimited stage small cell lung cancerStage small cell lung cancerSmall cell lung cancerModality therapyPulmonary toxicityPulmonary complicationsVital capacityLung cancerRadiation therapyLife-threatening pulmonary toxicityInitial pulmonary function testLower vital capacitySubsequent pulmonary complicationsBilateral pulmonary infiltratesDisease-free survivalModality armPulmonary infiltratesPulmonary morbidityExpiratory volumeOverall survivalPerformance statusProspective trialClinical courseHospital admission
1985
Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer.
Johnson B, Becker B, Goff W, Petronas N, Krehbiel M, Makuch R, McKenna G, Glatstein E, Ihde D. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. Journal Of Clinical Oncology 1985, 3: 1659-67. PMID: 2999346, DOI: 10.1200/jco.1985.3.12.1659.Peer-Reviewed Original ResearchConceptsProphylactic cranial irradiationMental status examinationLarge radiotherapy fractionsCranial irradiationStatus ExaminationScan abnormalitiesNeuropsychologic testingSmall-cell lung cancer trialHigh-dose induction chemotherapyLow-dose maintenance chemotherapySmall cell lung cancerRadiotherapy fractionsAbnormal neurologic examinationCranial tomography scanProgressive ventricular dilatationTherapeutic cranial irradiationTomography scan abnormalitiesHigh-dose chemotherapyStart of therapyLong-term survivorsLung cancer trialsMajority of casesCCT findingsInduction chemotherapyMaintenance chemotherapyPatients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up.
Johnson B, Ihde D, Bunn P, Becker B, Walsh T, Weinstein Z, Matthews M, Whang-Peng J, Makuch R, Johnston-Early A. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Annals Of Internal Medicine 1985, 103: 430-8. PMID: 2992337, DOI: 10.7326/0003-4819-103-3-430.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrainCarcinoma, Small CellCombined Modality TherapyFemaleFollow-Up StudiesHematologic DiseasesHumansLung NeoplasmsMaleMemory DisordersMiddle AgedNeoplasm Recurrence, LocalNervous System DiseasesRadiotherapyRespiratory Function TestsConceptsSmall cell lung cancerLung cancerCombination chemotherapyEvidence of cancerCancer-free survivalCell lung cancerCranial irradiationAggressive therapyLate toxicityUnrelated causesLate relapseTherapeutic trialsCancer 5PatientsPotential cureThirty-monthCancerChemotherapyRelapseCureChronic toxicityMonthsSurvivalEleven yearsToxicityEffects of fractionated irradiation of endocrine aspects of testicular function.
Shapiro E, Kinsella T, Makuch R, Fraass B, Glatstein E, Rosenberg S, Sherins R. Effects of fractionated irradiation of endocrine aspects of testicular function. Journal Of Clinical Oncology 1985, 3: 1232-9. PMID: 3928830, DOI: 10.1200/jco.1985.3.9.1232.Peer-Reviewed Original ResearchConceptsDose-dependent increaseGerm cell depletionCell depletionTesticular functionBaseline levelsFollicle-stimulating hormone valuesTotal testosterone valuesSerum FSH levelsMedian differenceLeydig cell dysfunctionSoft tissue sarcomasSerum follicle-stimulating hormone (FSH) valuesLeydig cell functionHigh-dose radiationLH changesTubule injuryFSH levelsOnly patientsSerum FSHLH concentrationsTesticular doseHormonal alterationsHormone valuesTumor bedRadiation injuryPrognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival
Ihde D, Matthews M, Makuch R, McIntire K, Eddy J, Seeff L. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. The American Journal Of Medicine 1985, 78: 399-406. PMID: 2579551, DOI: 10.1016/0002-9343(85)90330-4.Peer-Reviewed Original ResearchConceptsAlpha-fetoprotein levelsFibrolamellar carcinomaHepatocellular carcinomaSystemic chemotherapyNormal serum alpha-fetoprotein levelsHepatitis B serum markersNormal alpha-fetoprotein levelsSerum alpha-fetoprotein levelsElevated alpha-fetoprotein levelsAmbulatory performance statusHomogeneous clinical featuresAbsence of cirrhosisHepatitis B markersTime of diagnosisGroup of patientsInitiation of treatmentLack of jaundiceAmbulatory statusExtrahepatic metastasesPerformance statusImproved survivalIndolent coursePrognostic factorsClinical featuresSerum markers
1984
A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer.
Crane J, Nelson M, Ihde D, Makuch R, Glatstein E, Zabell A, Johnston-Early A, Bates H, Saini N, Cohen M. A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer. Journal Of Clinical Oncology 1984, 2: 1017-24. PMID: 6088707, DOI: 10.1200/jco.1984.2.9.1017.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerRadionuclide brain scanCell lung cancerBrain metastasesCT scanBrain scansAsymptomatic patientsNeurologic signsLung cancerExtensive-stage diseaseTherapeutic cranial irradiationTomographic brain scansCT brain scanSix-month intervalsCranial irradiationRN scansSCLC patientsAsymptomatic lesionsSymptomatic patientsSystemic therapyConsecutive patientsNeurologic historyComputed tomographyPatientsMetastasisDiagnosis and significance of liver metastases in small cell carcinoma of the lung.
Mulshine J, Makuch R, Johnston-Early A, Matthews M, Carney D, Ihde D, Cohen M, Bates H, Dunnick N, Minna J. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. Journal Of Clinical Oncology 1984, 2: 733-41. PMID: 6330314, DOI: 10.1200/jco.1984.2.7.733.Peer-Reviewed Original ResearchConceptsLiver function testsLiver metastasesLiver biopsyLiver scanFunction testsLiver evaluationSmall cell lung cancerNoninvasive procedureDisease-free survivorsPercutaneous liver biopsySmall cell carcinomaCell lung cancerRadionuclide liver scanResponse of patientsNational Cancer InstituteSuch metastasesLiver involvementConsecutive patientsStaging procedureHepatic metastasesPrognostic implicationsCell carcinomaPhysical examinationLung cancerCancer InstituteSecond malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsHodgkin's diseaseMalignant neoplasmsSolid tumorsNational Cancer Institute ExperienceChronic myeloid leukemiaCases of sarcomaRisk of leukemiaUntreated patientsPatient ageHodgkin's lymphomaMedical recordsInstitute experienceMyeloid leukemiaSimilar riskAge 40Treatment groupsPatientsGreater riskLeukemiaTen yearsDiseaseTumorsLymphomaPositive association